Arterial Occlusive Diseases
Welcome,         Profile    Billing    Logout  
 105 Companies   193 Products   193 Products   133 Mechanisms of Action   26 Trials   4426 News 


12345678910111213...8990»
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date:  Coronary Artery Risk Development in Young Adults (clinicaltrials.gov) -  Jul 22, 2024   
    P=N/A,  N=5115, Active, not recruiting, 
    Trial completion date: Sep 2008 --> Jun 2033 | Trial primary completion date: Sep 2008 --> Jun 2033 | Completed --> Active, not recruiting
  • ||||||||||  Fantom (sirolimus-eluting bioresorbable scaffold) / REVA Medical
    Trial completion date:  FANTOM II: Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold (clinicaltrials.gov) -  Jun 13, 2024   
    P=N/A,  N=220, Active, not recruiting, 
    Trial completion date: Sep 2008 --> Jun 2033 | Trial primary completion date: Sep 2008 --> Jun 2033 | Completed --> Active, not recruiting Trial completion date: Feb 2024 --> Sep 2024
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date, HEOR:  THORESCI: Tilburg Health Outcomes Registry of Emotional Stress in Coronary Intervention (clinicaltrials.gov) -  Apr 11, 2024   
    P=N/A,  N=3000, Recruiting, 
    Trial completion date: Jul 2025 --> Jul 2027 | Trial primary completion date: Jul 2025 --> Jul 2027 Trial completion date: Dec 2023 --> Dec 2037 | Trial primary completion date: Dec 2023 --> Dec 2027
  • ||||||||||  NN1213 / Novo Nordisk, Xience (everolimus-eluting stent) / Abbott
    Enrollment closed, Trial completion date:  A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II (clinicaltrials.gov) -  Oct 25, 2023   
    P=N/A,  N=430, Active, not recruiting, 
    Phase classification: P3 --> P=N/A Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Oct 2024
  • ||||||||||  NN1213 / Novo Nordisk
    Phase classification:  Oral Glutamine in Cardiopulmonary Bypass (clinicaltrials.gov) -  Oct 3, 2023   
    P=N/A,  N=28, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Oct 2024 Phase classification: P4 --> P=N/A
  • ||||||||||  Phase classification:  Women's Isoflavone Soy Health (WISH) Trial (clinicaltrials.gov) -  May 6, 2023   
    P2,  N=350, Completed, 
    Phase classification: P4 --> P3 Phase classification: P2/3 --> P2
  • ||||||||||  Phase classification:  Randomised Ischaemic Mitral Evaluation (RIME) Trial (clinicaltrials.gov) -  Mar 28, 2023   
    P1,  N=73, Completed, 
    Trial completion date: Mar 2023 --> Feb 2024 | Recruiting --> Active, not recruiting Phase classification: P3 --> P1
  • ||||||||||  bivalirudin / Generic mfg., clopidogrel / Generic mfg., enoxaparin sodium / Generic mfg.
    Enrollment change, Trial termination:  TACA: Anticoagulant Treatments and Percutaneous Coronary Angioplasty (clinicaltrials.gov) -  May 17, 2019   
    P4,  N=99, Terminated, 
    Phase classification: P3 --> P1 N=480 --> 99 | Recruiting --> Terminated; recruitment difficulties
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Stavanger UncomPlicatEd Elective PCI Same DaY Discharge Study (SPEEDY Study) (clinicaltrials.gov) -  May 1, 2019   
    P=N/A,  N=82, Completed, 
    Phase classification: P3 --> P=N/A Recruiting --> Completed | N=151 --> 82 | Trial completion date: Dec 2020 --> Nov 2018 | Trial primary completion date: Dec 2019 --> Nov 2018
  • ||||||||||  Trial completion date:  Graft Patency Analysis of the Right Coronary Artery System (clinicaltrials.gov) -  Apr 20, 2019   
    P=N/A,  N=50, Terminated, 
    Trial primary completion date: Oct 2020 --> Oct 2021 Trial completion date: Dec 2022 --> Dec 2018
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  DESTINY TRIAL (Inspiron x Biomatrix) (clinicaltrials.gov) -  Apr 20, 2019   
    P4,  N=170, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  NN1213 / Novo Nordisk
    Phase classification:  TurboHawk (clinicaltrials.gov) -  Apr 19, 2019   
    P=N/A,  N=51, Completed, 
    Recruiting --> Completed | Phase classification: P4 --> PN/A | N=1116 --> 568 Phase classification: P3 --> P=N/A
  • ||||||||||  NN1213 / Novo Nordisk
    Enrollment change, Trial termination:  The ABSORB Bioresorbable Scaffold Below the Knee (BTK) Study (clinicaltrials.gov) -  Apr 17, 2019   
    P=N/A,  N=4, Terminated, 
    Phase classification: P3 --> P=N/A N=60 --> 4 | Recruiting --> Terminated; Company have withdrawn the product
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Multi-modality Imaging in Acute Myocardial Infarction (clinicaltrials.gov) -  Apr 10, 2019   
    P=N/A,  N=62, Completed, 
    N=60 --> 4 | Recruiting --> Terminated; Company have withdrawn the product Recruiting --> Completed | N=100 --> 62 | Trial completion date: Jun 2020 --> Feb 2019 | Trial primary completion date: Jun 2019 --> Feb 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning (clinicaltrials.gov) -  Apr 5, 2019   
    P=N/A,  N=20, Completed, 
    Recruiting --> Completed | N=100 --> 62 | Trial completion date: Jun 2020 --> Feb 2019 | Trial primary completion date: Jun 2019 --> Feb 2019 Active, not recruiting --> Completed | Trial completion date: May 2018 --> May 2017 | Trial primary completion date: May 2018 --> Nov 2016
  • ||||||||||  Resolute ZES (zotarolimus-eluting stent) / Medtronic
    Trial completion:  Medtronic RESOLUTE ONYX Core (2.25 mm - 4.0 mm) Clinical Study (clinicaltrials.gov) -  Apr 3, 2019   
    P=N/A,  N=75, Completed, 
    Active, not recruiting --> Completed | Trial completion date: May 2018 --> May 2017 | Trial primary completion date: May 2018 --> Nov 2016 Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  ORACLE: Comparison of Orbital Versus Rotational Atherectomy Effects On Coronary Microcirculation in PCI (clinicaltrials.gov) -  Mar 26, 2019   
    P=N/A,  N=20, Completed, 
    Completed --> Terminated; As it is difficult to recruit any more subjects, the investigators decided to terminate the study. Recruiting --> Completed | N=40 --> 20 | Trial completion date: Sep 2017 --> Mar 2019 | Trial primary completion date: Sep 2017 --> Mar 2019
  • ||||||||||  Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Trial completion, Trial completion date, Trial primary completion date:  ADDENDA: Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery (clinicaltrials.gov) -  Mar 25, 2019   
    P4,  N=98, Completed, 
    Recruiting --> Completed | N=40 --> 20 | Trial completion date: Sep 2017 --> Mar 2019 | Trial primary completion date: Sep 2017 --> Mar 2019 Not yet recruiting --> Completed | Trial completion date: Oct 2017 --> Mar 2019 | Trial primary completion date: Jul 2017 --> Dec 2018
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  New Technologies to Determine Carotid Plaque Vulnerability (clinicaltrials.gov) -  Mar 6, 2019   
    P=N/A,  N=216, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Sep 2016 --> Jan 2019 | Trial primary completion date: Sep 2016 --> Oct 2018
  • ||||||||||  Phase classification:  Assessment of Coronary Plaque Composition (clinicaltrials.gov) -  Mar 5, 2019   
    P1,  N=39, Completed, 
    Recruiting --> Completed | Trial completion date: Sep 2016 --> Jan 2019 | Trial primary completion date: Sep 2016 --> Oct 2018 Phase classification: P=N/A --> P1
  • ||||||||||  Trial completion, Enrollment change:  Exercise for Women With Peripheral Arterial Disease (clinicaltrials.gov) -  Mar 1, 2019   
    P=N/A,  N=33, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=74 --> 33
  • ||||||||||  NN1213 / Novo Nordisk
    Phase classification:  EverFlex (clinicaltrials.gov) -  Mar 1, 2019   
    P=N/A,  N=34, Completed, 
    Recruiting --> Completed | N=74 --> 33 Phase classification: P4 --> P=N/A
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date, HEOR:  FFR-SELECT: Routine Versus Selective Use of FFR to Guide PCI (clinicaltrials.gov) -  Feb 26, 2019   
    P4,  N=261, Terminated, 
    Phase classification: P4 --> P=N/A Trial completion date: Apr 2016 --> Feb 2017 | Trial primary completion date: Apr 2015 --> Feb 2017
  • ||||||||||  Trial primary completion date:  Metabolomic Profile of Patients Undergoing Myocardial Perfusion SPECT (clinicaltrials.gov) -  Feb 25, 2019   
    P=N/A,  N=500, Active, not recruiting, 
    Trial completion date: Apr 2016 --> Feb 2017 | Trial primary completion date: Apr 2015 --> Feb 2017 Trial primary completion date: Oct 2018 --> Jun 2019
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion:  BackonBike: a Bike Application to Support Cardiac Patient (clinicaltrials.gov) -  Feb 21, 2019   
    P=N/A,  N=75, Completed, 
    Trial primary completion date: Oct 2018 --> Jun 2019 Recruiting --> Completed
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Adverse events:  Metabolic, Vascular and Cognitive Effects of Treatment With Anthocyanins (clinicaltrials.gov) -  Feb 18, 2019   
    P=N/A,  N=54, Completed, 
    Phase classification: P2/3 --> P=N/A Active, not recruiting --> Completed | Trial completion date: Nov 2020 --> Nov 2018
  • ||||||||||  NN1213 / Novo Nordisk
    Trial completion, Trial completion date, Trial primary completion date:  Assessment of Thrombotic Status in Patients at Risk of Cardiovascular Thrombosis (clinicaltrials.gov) -  Feb 8, 2019   
    P=N/A,  N=140, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Apr 2018 --> Feb 2019 Recruiting --> Completed | Trial completion date: Mar 2018 --> Sep 2018 | Trial primary completion date: Mar 2018 --> Sep 2018